Technologies for diabetes genomics.
The genetic risk for diabetes largely depends on the type of diabetes and the penetrance and severity of the effect of the contributing genes. This ranges from the high-risk mutations of neonatal diabetes and maturityonset diabetes of the young to the lower, but still significant, risk conferred by common human leukocyte antigen alleles in type 1 diabetes to the still-lower risk conferred by the common variants associated with type 2 diabetes. There are many new molecular technologies, each with their own set of methodological issues, that have been used for genome-wide association studies and that can be used for determining the genetic risk for these various types of diabetes. These technologies include whole genome single nucleotide polymorphism microarrays, high-throughput polymorphism analyzers, next-generation sequencers, and copy-number variant technologies.
Centers for Disease Control and Prevention, Atlanta, Georgia 30041, USA. pwm2@cdc.gov
Patricia W
PW
Mueller
D003924:Diabetes Mellitus, Type 2 / Q000235:genetics*; D005820:Genetic Testing / Q000379:methods; D015894:Genome, Human / Q000235:genetics; D055106:Genome-Wide Association Study / Q000295:instrumentation / Q000379:methods; D023281:Genomics / Q000295:instrumentation* / Q000379:methods; D006801:Humans